AlloVir CEO Departs, CFO Steps In

Dow Jones
2024-12-21

By Katherine Hamilton

AlloVir said its chief executive Diana Brainard is departing and the company has appointed its CFO to take her place.

Brainard's departure became effective Thursday and she resigned as director of the cell therapy company, the company said on Friday. Her resignation did not result from any disagreement with the company related to its operations, policies or practices, AlloVir said.

AlloVir said it plans to give Brainard a lump sum in cash worth 36 months of her base salary, which was $623,432 in 2023, according to a filing. She is also set to receive $100,000 for completing the proposed merger with Kalaris Therapeutics.

To succeed Brainard, AlloVir appointed Vikas Sinha, who has been serving as chief financial officer since 2019. Sinha, 61, co-founded ElevateBio and was previously CFO of Alexion Pharmaceuticals.

Sinha' earned a total compensation of $2.9 million as CFO in 2023. Brainard made a total of $6.1 million as CEO that year.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 20, 2024 17:40 ET (22:40 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10